Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix Revenues Almost Double in Q2

NEW YORK – Quanterix reported after the close of the market on Thursday that its second quarter revenues were up 93 percent year over year.

The company posted Q2 revenues of $25.4 million, up from $13.1 million in Q2 2020 and above the consensus Wall Street estimate of $23.4 million.

Its Q2 product revenues rose almost threefold to $18.7 million from $6.8 million in Q2 2020. Service and other revenues were down 11 percent to $5.6 million from $6.3 million in the prior-year period.

"The past quarter has proven to be a pivotal time for our company as we continue to make immense strides with our strategic expansion in the diagnostics space," Kevin Hrusovsky, Quanterix's chairman, CEO, and president, said in a statement, noting in particular the company's role in diagnosing and monitoring neurodegenerative conditions like Alzheimer's disease.

The firm's Q2 net loss fell to $11.9 million from $12.3 million a year ago. It didn't provide a loss per share figure. Analysts, on average, had predicted a net loss of $.33 per share.

Quanterix's R&D spending during the quarter was up 57 percent to $6.8 million from $4.3 million in Q2 2020, and its SG&A expenses rose 59 percent to $20.8 million from $13.1 million the year before.

The company ended the quarter with $430.8 million in cash and cash equivalents.

In morning trading on the Nasdaq, Quanterix shares were down almost 6 percent at $53.80.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.